Selective targeting of cancer cells using synthetic peptides

被引:143
作者
Shadidi, M [1 ]
Sioud, M [1 ]
机构
[1] Norwegian Radium Hosp, Inst Canc Res, Mol Med Grp, Dept Immunol, N-0310 Oslo, Norway
关键词
phage display; targeting peptides; liposomes; gene therapy; angiogenesis;
D O I
10.1016/j.drup.2003.11.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To establish efficient and reliable therapeutic delivery into cancer cells, a number of delivery agents and concepts have been investigated in the recent years. Among many improvements in targeted and controlled delivery of therapeutics, cell-targeting peptides have emerged as the most valuable non-immunogenic approach to target cancer cells. Peptides can be incorporated into multicomponent gene-delivery complexes for cell-specific targeting. In contrast to larger molecules such as monoclonal antibodies, peptides have an excellent tumor penetration, which make them ideal carriers of therapeutics to the site of primary tumor and the distant metastatic sites. Here we give an update on the progress made during the last two years on the identification and potential of specific synthetic tumor targeting peptides. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:363 / 371
页数:9
相关论文
共 110 条
[1]   Converting a peptide into a drug: Strategies to improve stability and bioavailability [J].
Adessi, C ;
Soto, C .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) :963-978
[2]   Therapeutic cancer targeting peptides [J].
Aina, OH ;
Sroka, TC ;
Chen, ML ;
Lam, KS .
BIOPOLYMERS, 2002, 66 (03) :184-199
[3]   The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery [J].
Alaoui-Jamali, MA ;
Qiang, H .
DRUG RESISTANCE UPDATES, 2003, 6 (02) :95-107
[4]   Molecular mechanisms of lymphangiogenesis in health and disease [J].
Alitalo, K ;
Carmeliet, P .
CANCER CELL, 2002, 1 (03) :219-227
[5]   Towards a novel classification of human malignancies based on gene expression patterns [J].
Alizadeh, AA ;
Ross, DT ;
Perou, CM ;
van de Rijn, M .
JOURNAL OF PATHOLOGY, 2001, 195 (01) :41-52
[6]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[7]   Steps toward mapping the human vasculature by phage display [J].
Arap, W ;
Kolonin, MG ;
Trepel, M ;
Lahdenranta, J ;
Cardó-Vila, M ;
Giordano, RJ ;
Mintz, PJ ;
Ardelt, PU ;
Yao, VJ ;
Vidal, CI ;
Chen, L ;
Flamm, A ;
Valtanen, H ;
Weavind, LM ;
Hicks, ME ;
Pollock, RE ;
Botz, GH ;
Bucana, CD ;
Koivunen, E ;
Cahill, D ;
Troncoso, P ;
Baggerly, KA ;
Pentz, RD ;
Do, KA ;
Logothetis, CJ ;
Pasqualini, R .
NATURE MEDICINE, 2002, 8 (02) :121-127
[8]   Targeting the prostate for destruction through a vascular address [J].
Arap, W ;
Haedicke, W ;
Bernasconi, M ;
Kain, R ;
Rajotte, D ;
Krajewski, S ;
Ellerby, HM ;
Bredesen, DE ;
Pasqualini, R ;
Ruoslahti, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) :1527-1531
[9]   Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ [J].
Arnt, CR ;
Chiorean, MV ;
Heldebrant, MV ;
Gores, GJ ;
Kaufmann, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (46) :44236-44243
[10]   Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels [J].
Asai, T ;
Nagatsuka, M ;
Kuromi, K ;
Yamakawa, S ;
Kurohane, K ;
Ogino, K ;
Tanaka, M ;
Taki, T ;
Oku, N .
FEBS LETTERS, 2002, 510 (03) :206-210